Abstract
The estrogen receptor (ER) is the most valuable target in cancer therapeutics. The ER signal transduction pathway controls breast and endometrial tumor cell replication. Members of the group of medicines called Selective ER Modulators such as tamoxifen or raloxifene are antiestrogenic in the breast tumor but can build bone in postmenopausal women. Tamoxifen is used ubiquitously to treat all stages of breast cancer and to prevent breast cancer in high-risk women. Raloxifene is used to prevent breast cancer in high-risk postmenopausal women as to treat osteoporosis and prevent breast cancer at the same time.
Original language | English (US) |
---|---|
Title of host publication | Cancer Therapeutic Targets |
Publisher | Springer New York |
Pages | 997-1006 |
Number of pages | 10 |
Volume | 2-2 |
ISBN (Electronic) | 9781441907172 |
ISBN (Print) | 9781441907165 |
DOIs | |
State | Published - Jan 1 2017 |
Keywords
- Antihormone therapy
- Assessment
- Decision network
- ERa
- ERß
- Estrogen receptor (ER)
- Hormone receptor
- Long-term antihormone therapy
- Luminal A and B intrinsic subtypes
- Nuclear receptor coregulator recruitment
- Oophorectomy
- Paradox
- Prognosis
- Raloxifene
- Role in breast cancer
- SERMs
- Selective serotonin reuptake inhibitors (SSRIs)
- Tamoxifen
- Therapeutics
ASJC Scopus subject areas
- General Medicine
- General Biochemistry, Genetics and Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics(all)